C1orf87 Inhibitors
C1orf87 Inhibitors are a group of chemical compounds that reduce the functional activity of C1orf87 through their influence on a variety of signaling pathways and processes. For instance, the activity of protein kinases is critical for the function of C1orf87. Staurosporine, as a kinase inhibitor, can therefore prevent the phosphorylation-dependent activation of C1orf87, leading to its functional diminishment. Similarly, LY 294002 and Wortmannin notably inhibit PI3K, which, if responsible for signaling events that activate C1orf87, would result in decreased activity of the protein when these inhibitors are present. The role of mTOR in cell proliferation and its potential regulation of C1orf87 suggests that Rapamycin could act as an indirect inhibitor, while PD 98059 and U0126, both targeting the MAPK pathway by inhibiting MEK, would also result in a decrease in C1orf87 activity if this protein operates downstream of the MAPK signaling.
The inhibitors targeting MAPK family members, such as SB 203580 against p38 and SP600125 against JNK, could similarly lead to reduced C1orf87 activity by disrupting the pathways that may regulate or activate it. Dasatinib's broad inhibition of tyrosine kinases could also decrease C1orf87 activity by blocking the phosphorylation it requires. Bortezomib's mechanism, which prevents proteasomal degradation, implies that C1orf87's activity could be regulated by its stability; thus, Bortezomib would diminish its function by altering its degradation process. Multi-kinase inhibitor Sorafenib, by targeting RAF kinases and potentially others involved in C1orf87's regulation, could also lead to reduced protein activity. Finally, ZM-447439's specific inhibition of Aurora kinases would impact C1orf87 if it is involved in cell cycle regulation mediated by these kinases, resulting in a downregulation of its activity. Collectively, these inhibitors exert their effects by targeting distinct cellular processes that converge on the functional diminishment of C1orf87.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. C1orf87 is a protein that, in its active form, is dependent on specific phosphorylation events. Inhibition of these kinases by Staurosporine would prevent activation of C1orf87, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a specific inhibitor of PI3K. PI3K signaling is integral to many cellular processes including those potentially involving C1orf87. By inhibiting PI3K, LY 294002 can diminish C1orf87 activity that is reliant on PI3K pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR, which is part of the cellular growth and proliferation pathway. If C1orf87 functions downstream or is regulated by mTOR signaling, rapamycin would indirectly diminish C1orf87 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an inhibitor of MEK, which works upstream of ERK in the MAPK pathway. If C1orf87 activity is enhanced by MAPK signaling, inhibiting MEK with PD 98059 would lead to decreased functional activity of C1orf87. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 inhibits p38 MAPK, which is involved in stress responses. Inhibition of p38 MAPK by SB 203580 could diminish the activity of C1orf87 if it is regulated by or associated with stress response pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key components of the MAPK pathway. If C1orf87 is activated by MAPK signaling, inhibition by U0126 will diminish its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent, irreversible inhibitor of PI3K. By inhibiting PI3K, Wortmannin can decrease the activity of C1orf87 if it is dependent on PI3K-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is a part of the MAPK pathway. JNK signaling can regulate various proteins, and if C1orf87 is one of them, SP600125 would reduce its activity by inhibiting JNK. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor. If C1orf87 activity is modulated by tyrosine kinase signaling, Dasatinib would lead to a decrease in its activity by inhibiting these kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. If C1orf87 is regulated through proteasomal degradation, its activity could be diminished by preventing its degradation with Bortezomib. | ||||||